Brief: Galapagos presented new data at ICML 2025 from Cohort 3 of ATALANTA-1 in relapsed/refractory indolent NHL patients
18/06/2025 22:44
June 18 (Reuters) - Galapagos NV GLPG.AS: GALAPAGOS PRESENTED NEW DATA AT ICML 2025 FROM COHORT 3 OF ATALANTA-1 IN RELAPSED/REFRACTORY INDOLENT NHL PATIENTS, DEMONSTRATING HIGH COMPLETE RESPONSE AND MRD NEGATIVITY RATES WITH CAR-T CANDIDATE GLPG5101 Source text: ID:nGNX8fqXv5 Further company coverage: GLPG.AS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors